BioSpace News Archive

Today the company launched its inaugural, annual National Health System Crisis Readiness Survey, which will assess operational strengths and weaknesses around crisis preparedness.

Biocare Medical , a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces a collaborative partnership with Bethyl Laboratories to develop targeted antibodies for cancer research and oncology diagnostics. Bethyl Laboratories has 45 years of experience in

RaySearch Laboratories AB has announced that by using a machine learning algorithm in treatment planning RayStation®*, Mälar Hospital in Eskilstuna, Sweden, has made significant time savings in dose planning for radiation therapy.

Immunovia AB (publ) (“Immunovia”) today announced the company will be presenting at the 52 nd EPC-IAP annual meeting on July 2 , 2020. This year’s event will be held virtually and will be the place to watch and listen to great lectures and latest research in Pancreatology. The registration for this year’s event is open and can be ma

GTCR, a leading private equity firm, announced today that its Cedar Gate Technologies (“Cedar Gate”) management partnership with CEO David Snow has acquired Citra Health Solutions (“Citra”). Citra sells a specialty workflow software solution

American Diabetes Association, Black Lives Matter, NAACP, AARP and others urge Congress to make testing more accessible through mobile units, community health workers and other means

Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for its xMAP® SARS-CoV-2 Multi-Antigen IgG assay

Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that it intends to offer and sell, subject to market and other conditions, $400 million of its common stock in an underwritten public offering.

Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the “Meeting”).

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases